We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 12.47 | 1.15% | 1,094.575 | 1,094.02 | 1,095.32 | 1,100.08 | 1,079.0855 | 1,087.89 | 150,228 | 20:22:49 |
From Jul 2021 to Jul 2024
By Colin Kellaher
Shares of Checkmate Pharmaceuticals Inc. more than quadrupled in premarket trading Tuesday after the clinical-stage biopharmaceutical company agreed to be acquired by Regeneron Pharmaceuticals Inc. for about $250 million.
Regeneron is paying $10.50 a share in cash for Checkmate, more than four times Monday's closing price of $2.41 for the Cambridge, Mass., company and more than 30% above the stock's 52-week high of $7.97 reached last May.
The deal is slated to close by mid-year.
Checkmate shares were recently changing hands at $10.40, up 332%, in premarket trading, while Regeneron shares slipped 0.4% to $720.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 19, 2022 09:31 ET (13:31 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
